cnl_21

Epac - Associazione Onlus

Portale Epatite e malattie del fegato

Portale Epatite e malattie del fegato

Portale Epatite e malattie del fegato

Portale Epatite e malattie del fegato

Portale Epatite e malattie del fegato

Portale Epatite e malattie del fegato

Portale Epatite e malattie del fegato

Malattie autoimmuni

Fai una donazione

Sostieni EpaC Onlus

Newsletter EpaC

Aggiornati via email. Iscriviti

Notiziario Epac

Periodico cartaceo. Iscriviti

Sangue Infetto

Visita il sito - legge 210/92

News nuovi farmaci in Inglese

A 12-Week Interferon-Free Regimen of ABT-450/r + ABT-333 + Ribavirin Achieved SVR12 in More Than 90% of Treatment-Naïve HCV Genotype-1-Infected Subjects and 47% of Previous Non-Responders

04/05/2012

Potent Viral Suppression With the All-Oral Combination of Daclatasvir (NS5A Inhibitor) and GS-7977 (Nucleotide NS5B Inhibitor), +/- Ribavirin, in Treatment-Naive Patients With Chronic HCV GT1, 2, or 3 (100% SVR gt1, 91% gt2)

04/05/2012

Interferon-Free Regimens at EASL

04/05/2012

12-Week Interferon-Free Regimen of ABT-450/r+ABT-333+Ribavirin Achieved SVR12 in More Than 90% of Treatment-Naïve HCV Genotype-1-Infected Subjects and 47% of Previous Non-Responders

20/04/2012

A 12-Week Interferon-Free Regimen of ABT-450/r, ABT-072, and Ribavirin was Well Tolerated and Achieved Sustained Virologic Response in 91% Treatment-Naïve HCV IL28B-CC Genotype-1-Infected Subject

20/04/2012

DUAL ORAL THERAPY WITH THE NS5A INHIBITOR DACLATASVIR (BMS-790052) AND NS3 PROTEASE INHIBITOR ASUNAPREVIR (BMS-650032) IN HCV GENOTYPE 1B-INFECTED NULL RESPONDERS OR INELIGIBLE/INTOLERANT TO PEGINTERF

20/04/2012

Title Safety OF TELAPREVIR or Boceprevir IN COMBINATION WITH Peginterferon alfa/Ribavirin, in CIRRHOTIC NON RESPONDERS. FIRST RESULTS OF THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC)

20/04/2012

Sustained Virologic Response (SVR) in Prior PegInterferon/ribavirin (PR) Treatment Failures After Retreatment with Boceprevir (BOC) + PR: The PROVIDE Study Interim Results

20/04/2012

TMC435 IN PATIENTS INFECTED WITH HCV GENOTYPE 1 WHO HAVE FAILED PREVIOUS PEGYLATED INTERFERON/RIBAVIRIN TREATMENT: VIROLOGIC ANALYSES OF THE ASPIRE TRIAL

20/04/2012

Low accelerating dose individualised duration treatment regimen for recurent HCV post liver transplantation

20/04/2012

Intravenous Silibinin -therapy in patients with chronic Hepatitis C in the transplant setting

20/04/2012

INTERFERON-FREE TREATMENT WITH A COMBINATION OF MERICITABINE AND DANOPREVIR/R WITH OR WITHOUT RIBAVIRIN IN TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED PATIENTS

20/04/2012

CONFIRMATION THAT QUADRUPLE THERAPY WITH DACLATASVIR (NS5A INHIBITOR), ASUNAPREVIR (NS3 INHIBITOR) AND PEGINTERFERON/RIBAVIRIN RESULTS IN HIGH RATE OF SVR4 IN HCV GENOTYPE 1 NULL RESPOND

20/04/2012

RESULTS OF ENABLE 2, A PHASE 3, MULTICENTER STUDY OF ELTROMBOPAG AND PEGINTERFERON ALFA-2B TREATMENT IN PATIENTS WITH HEPATITIS C AND THROMBOCYTOPENIA

20/04/2012

COMPARISON OF TWO QUANTITATIVE HCV RNA ASSAYS IN SAMPLES FROM PATIENTS TREATED WITH A PROTEASE INHIBITOR-BASED THERAPY: IMPLICATIONS FOR RESPONSE GUIDED THERAPY

20/04/2012

Daclatasvir + GS7977 data leak

10/04/2012

Abbott to Present Positive Phase 2 Results from Multiple Interferon-Free Studies of Combination Regimens for the Treatment of Hepatitis C

06/04/2012

GILEAD ANNOUNCES DATA FOR GENOTYPE 1 NULL RESPONDER, HEPATITIS C PATIENTS ENROLLED IN ELECTRON STUDY

19/02/2012

Hepatitis C Clinic Operated by Infectious Disease Specialists at a Comprehensive Cancer Center: Help Is on the Way

19/02/2012

BioCryst Reveals Favorable Preclinical Results For Nucleotide BCX5191 For Hepatitis C

17/02/2012

Pagina:

6 7 8

© Copyright 2015 - Associazione EpaC Onlus - C.F. 97375600158

Via Col. Tommaso Masala, 42
C/O Parco Altamira - 00148 Roma

Tel. 06.60200566 | Fax 06.60209056
Orari ufficio: 9.00-12.00 e 14.00-17.00

Via Luigi Cadorna, 17/A
20871 Vimercate Monza e Brianza

Tel. 0396083527 | Fax 039 6611523
Orari ufficio: 9.00-12.00 e 14.00-17.00

ACE - Alleanza Contro Epatiti World Hepatitis Alliance ELPA - European Liver Patients Associations